Actively Recruiting
Study of Immunotherapy Biomarkers to Guide First and Second-Line Treatments in Advanced Non-Small Cell Lung Cancer
Led by City of Hope Medical Center · Updated on 2026-10-16
535
Participants Needed
13
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating biomarkers to predict how patients with stage IIIB-IV non-small cell lung cancer NSCLC respond to first-line immunotherapy using PD1 or PD-L1 based treatments and to guide second-line treatment choices. This phase II trial explores how changes in circulating tumor DNA ctDNA in the blood may help identify treatment failure early and personalize therapy. The study also investigates second-line immunotherapies for patients whose cancer progresses, including treatments targeting specific genetic mutations. Participants first receive PDL1-based immunotherapy with or without chemotherapy every three weeks for up to 12 to 24 months. Those who respond well after 12 months may either stop or continue therapy up to 24 months under different study arms. After 24 months, patients may stop or continue treatment based on disease status. Patients with disease progression enter a second phase receiving second-line immunotherapy regimens such as tremelimumab with durvalumab or adagrasib with bevacizumab. Treatments are given according to specific schedules and continue unless disease worsens or side effects occur. Throughout the study, participants undergo regular blood sampling to measure ctDNA, imaging tests including CT, MRI, or PET scans, and may have tumor biopsies and fluid collections as part of routine care. After treatment ends, follow-up occurs at 30 days, then every three months for a year, and every six months up to two years. The main outcomes measured include progression-free survival during first and second-line treatments, overall survival, ctDNA changes, treatment response, and safety events. This trial helps improve personalized treatment strategies for advanced NSCLC.
CONDITIONS
Brief Title
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here